February 29, 2024
Genomate Health Caps Off 2023 with Participation in Key Industry Events

Genomate Health, trailblazer in precision oncology solutions, concludes a remarkable December 2023 by attending and speaking at noteworthy conferences across the United States. Moreover, the team is celebrating the completion of the two-year MIT REAP - Regional Entrepreneurship Acceleration Program of MIT Sloan School of Management.

Event Highlights:

17th Annual Personalized Medicine Conference

November 30 – December 1, 2023, Dana Point, CA

We were honored to contribute our expertise and insights at the renowned Personalized Medicine Conference, engaging with industry leaders and shaping the discourse on the future of personalized medicine. The event brought together leading minds in the field, providing Genomate with a platform to showcase its groundbreaking AI-driven solutions for precision oncology.

Istvan Petak, CEO, and Sean Khozin, Advisor on Medical Affairs & Regulatory Strategy, at PMC 2023

MedInvest Conference

December 5 – 6, 2023, Palo Alto, CA

Genomate Health proudly showcased our AI-driven solutions at the MedInvest Conference, fostering collaboration with investors and fellow healthcare innovators. The conference served as a key forum for networking and collaboration, aligning with Genomate Health's commitment to advancing innovation in the healthcare sector.

New England Venture Summit

December 12 – 13, 2023, Boston, MA

We wrapped up this eventful month by attending the New England Venture Summit in Boston, MA. The summit provided Genomate Healthwith a valuable platform to engage with venture capitalists, industry experts, and fellow innovators.

Istvan Petak, Genomate Health CEO presenting at New England Venture Summit

CEO Istvan Petak Completes MIT REAP Program

In a significant milestone, Genomate Health's CEO, Istvan Petak, successfully completed the two-year MIT REAP (Regional Entrepreneurship Acceleration Program) offered by the MIT Sloan School of Management. Reflecting on this achievement, Istvan Petak stated, “I thank my teammates from Scaleup Hungary and the outstanding faculty of MIT. It was an extraordinary experience to meet other founders and innovation ecosystem stakeholders from different world regions working on solutions for humanity's problems, from cancer to climate change". He continued, "These shared challenges unite us all around the globe. We, at Genomate Health, are developing solutions for precision oncology that we hope cancer patients will benefit from in every country."

Istvan Petak with MIT REAP Program proof of completion

Genomate Health looks forward to leveraging the insights gained from these events to further enhance its precision oncology solutions and contribute to the global fight against cancer. Genomate Health is a leader in precision oncology, utilizing AI-driven solutions to revolutionize cancer care. With a commitment to innovation and a focus on personalized treatment strategies, Genomate Health aims to improve patient outcomes and reshape the future of cancer treatment.

These strategic engagements and achievements underscore Genomate Health's commitment to advancing precision oncology on a global scale. As the company continues to pioneer innovations in cancer care, it remains dedicated to making a positive impact on the lives of patients worldwide.

About Genomate Health

Genomate Health Inc. is a digital health company (based in Cambridge, MA) that develops AI-powered computational tools for personalized medicine. Its main focus is assisting physicians in making optimal personalized treatment decisions for each patient based on the complex molecular characteristics of human diseases.

Its flagship product, Genomate® MTC (Molecular Treatment Calculator), is a powerful computational (open box AI) tool aiming to optimize treatment decision-making in precision oncology by automated data compilation, evaluation, and synthesis in a knowledge model allowing standardized, personalized treatment decisions based on the totality of available molecular information. The company’s goal is to make this solution globally available to cancer patients and their oncologists in 2023. For more information, visit www.genomate.health, and follow the momentum on Facebook, Twitter, Instagram, and LinkedIn.

Media Inquiries:

Alina Luchian
Brand Manager, Genomate Health Inc